|
06-2025
|
HCV-TARGET ADMIN CORE
HCV-TARGET ADMIN CORE
|
|
06-2024
|
COM CTSI Institutional Support
COM CTSI Institutional Support
|
|
06-2024
|
OoR Matching Support for CTSI
OoR Matching Support for CTSI
|
|
06-2024
|
HSC COM Matching Commitment
HSC COM Matching Commitment
|
|
06-2024
|
Florida Academic Cancer Center Alliance Seed Grants
Florida Academic Cancer Center Alliance Seed Grants
|
|
06-2023
|
Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
|
|
06-2023
|
Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
Collaborating to Advance Teaching and Learning of Science Educators and Students (CATALySES)
|
|
06-2023
|
A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials"
|
|
04-2023
|
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
|
|
03-2022
|
Prioritize Study
Prioritize Study
|
|
09-2021
|
HCV TARGET: Biorepository Specimen Bank
HCV TARGET: Biorepository Specimen Bank
|
|
06-2021
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
06-2021
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
06-2021
|
CTSI Institutional Support
CTSI Institutional Support
|
|
06-2021
|
CTSI Institutional Support
CTSI Institutional Support
|
|
06-2021
|
HCV-TARGET Biorepository Specimen Bank
HCV-TARGET Biorepository Specimen Bank
|
|
03-2021
|
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
|
|
12-2020
|
CTSI
CTSI
|
|
12-2020
|
CTSI
CTSI
|
|
12-2020
|
CTSI
CTSI
|
|
12-2020
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
|
|
12-2020
|
21st Century Research & Economic Development Investment Program (REDIP)
21st Century Research & Economic Development Investment Program (REDIP)
|
|
06-2020
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
06-2020
|
COM CTSI Institutional Matching Support Year 3-4
COM CTSI Institutional Matching Support Year 3-4
|
|
02-2020
|
Lawton Family Liver Research - UFF Fund #008386
Lawton Family Liver Research - UFF Fund #008386
|
|
02-2020
|
Res and Dev Gastroenterology - UFF Fund #002739
Res and Dev Gastroenterology - UFF Fund #002739
|
|
12-2019
|
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
|
|
12-2019
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
|
|
11-2019
|
GS-US-248-0122, #A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
GS-US-248-0122, #A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
|
|
07-2019
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
10-2018
|
Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
|
|
10-2018
|
Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
Stakeholder Engagement and Multi-Risk Assessment in Dental Care Settings
|
|
10-2018
|
Safety of Direct Acting Antiviral Medications for Hepatitis C
Safety of Direct Acting Antiviral Medications for Hepatitis C
|
|
10-2018
|
Safety of Direct Acting Antiviral Medications for Hepatitis C
Safety of Direct Acting Antiviral Medications for Hepatitis C
|
|
09-2018
|
BMS AI444-257 A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
BMS AI444-257 A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
|
|
09-2018
|
GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who DidNot Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
GS-US-248-0123 A Long Term Follow-up Registry Study of Subjects Who DidNot Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
|
|
09-2018
|
Genomic Medicine Implementation: The Personalized Medicine Program
Genomic Medicine Implementation: The Personalized Medicine Program
|
|
09-2018
|
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Subjects with Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Subjects with Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)
|
|
07-2018
|
Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
|
|
07-2018
|
Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
Patient Reported Outcomes Project of HCV-Target (Prop up TARGET)
|
|
03-2018
|
The National Dental PBRN FY18
The National Dental PBRN FY18
|
|
03-2018
|
The National Dental PBRN FY18
The National Dental PBRN FY18
|
|
03-2018
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
02-2018
|
A single arm, open label study to evaluate the efficacy and satety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1,2,4,5 or 6 infection and compensated Cirrhosis
A single arm, open label study to evaluate the efficacy and satety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1,2,4,5 or 6 infection and compensated Cirrhosis
|
|
11-2017
|
'A PHASE 3B STUDY OF 2 TX DURATIONS OF TELAPREVIR, PEGASYS, AND COPEGUS IN TREATMENT-NAIVE AND PRIOR RELAPSER SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND IL28B CC GENOTYPE'
'A PHASE 3B STUDY OF 2 TX DURATIONS OF TELAPREVIR, PEGASYS, AND COPEGUS IN TREATMENT-NAIVE AND PRIOR RELAPSER SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND IL28B CC GENOTYPE'
|
|
10-2017
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
|
|
09-2017
|
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
|
|
09-2017
|
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
|
|
08-2017
|
Acute Alcohol and Calcium-Dependent LPS-Triggered Activa
Acute Alcohol and Calcium-Dependent LPS-Triggered Activa
|
|
07-2017
|
The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
|
|
07-2017
|
The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)
|
|
06-2017
|
'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
|
|
04-2017
|
The National Dental PBRN
The National Dental PBRN
|
|
04-2017
|
The National Dental PBRN
The National Dental PBRN
|
|
03-2017
|
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE HEALTH ,
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE HEALTH ,
|
|
03-2017
|
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TOIMPROVE HEALTH
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TOIMPROVE HEALTH
|
|
02-2017
|
MK-5172 'A PHASE II/II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH HCV AND CHRONIC KIDNEY DISEASE'
MK-5172 'A PHASE II/II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH HCV AND CHRONIC KIDNEY DISEASE'
|
|
02-2017
|
IDX-03YF '3-YEAR, Observ Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, DAA'
IDX-03YF '3-YEAR, Observ Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, DAA'
|
|
12-2016
|
Evaluation of Baseline HCV Resistance mutations in Genotype1 patients initiating tretamnent in real-world settings
Evaluation of Baseline HCV Resistance mutations in Genotype1 patients initiating tretamnent in real-world settings
|
|
12-2016
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
|
|
12-2016
|
GS-US-196-0123
GS-US-196-0123
|
|
10-2016
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
|
|
10-2016
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study
|
|
10-2016
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study
|
|
09-2016
|
AbbVie M13-102 'A Follow-up Study to Assess Resistance and Durability of Response to AbbVie DAA Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the TX of Chronic HCV Infection' (AbbVie Protocol M13-102)
AbbVie M13-102 'A Follow-up Study to Assess Resistance and Durability of Response to AbbVie DAA Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the TX of Chronic HCV Infection' (AbbVie Protocol M13-102)
|
|
09-2016
|
BMSAI444011
BMSAI444011
|
|
08-2016
|
Clinical and Translational Science Institute
Clinical and Translational Science Institute
|
|
08-2016
|
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
|
|
07-2016
|
Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD)
Validation of an Observer Reported Outcome (ObsRO) Measure of Home Functionality in Children with Pyruvate Dehydrogenase Complex Deficiency (PDCD)
|
|
04-2016
|
A Randomized Study to Evaluate the Safety and Efficacy of IDX179 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection'
A Randomized Study to Evaluate the Safety and Efficacy of IDX179 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection'
|
|
03-2016
|
Together: Transforming and Translating Discovery to Improve Health
Together: Transforming and Translating Discovery to Improve Health
|
|
03-2016
|
UF CTSI NRSA Training Core
UF CTSI NRSA Training Core
|
|
03-2016
|
UF CTSI NRSA Training Core
UF CTSI NRSA Training Core
|
|
03-2016
|
GS-US-337-0108 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir FDC ? RBV for 8 Wks and Sofosbuvir/Ledipasvir FDC Combo for 12 Wks in Tx-Na?ve Subjects with Chronic Genotype 1 HCV'
GS-US-337-0108 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir FDC ? RBV for 8 Wks and Sofosbuvir/Ledipasvir FDC Combo for 12 Wks in Tx-Na?ve Subjects with Chronic Genotype 1 HCV'
|
|
03-2016
|
VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
|
|
03-2016
|
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
|
|
02-2016
|
AI444-218 'A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Na?ve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection'
AI444-218 'A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Na?ve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection'
|
|
01-2016
|
BI 201335 and BI 207127 Combination Therapy in Treatment -Naive HCV Patients
BI 201335 and BI 207127 Combination Therapy in Treatment -Naive HCV Patients
|
|
12-2015
|
GS-US-337-0109 'G??A Phase 3, Multicenter, Randomized, Open-Label Study for Efficacy and Safety of Sofosbuvir/GS-5885 FDC -? Ribavirin for 12 & 24 Weeks in Treatment-Experienced Subjects w/Chronic Genotype 1 HCV InfectionG??
GS-US-337-0109 'G??A Phase 3, Multicenter, Randomized, Open-Label Study for Efficacy and Safety of Sofosbuvir/GS-5885 FDC -? Ribavirin for 12 & 24 Weeks in Treatment-Experienced Subjects w/Chronic Genotype 1 HCV InfectionG??
|
|
11-2015
|
Nelson Abbott M13-099 'A Randomized, Open-label Study of ABT 450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 W RBV in Geno 1 (HCV) Infection and Human Cirrhosis (TURQUOISE-II)'
Nelson Abbott M13-099 'A Randomized, Open-label Study of ABT 450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 W RBV in Geno 1 (HCV) Infection and Human Cirrhosis (TURQUOISE-II)'
|
|
11-2015
|
Abbott M13-101
Abbott M13-101
|
|
10-2015
|
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
Abbott M11-646 'A Randomized, Double-blind, Placebo-controlled Study to Evaluate te Efficacy and Safety of ABT-450/Ritonivair/ABT-267 (ABT-450/R/ABT-267) and ABT-333 Co-administered with RBV in Treatment-Naive Adults with Geno 1 Chronic (HCV) '
|
|
09-2015
|
CTSA
CTSA
|
|
09-2015
|
CTSA
CTSA
|
|
09-2015
|
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
GS-US-337-0102 'A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV'
|
|
08-2015
|
Magnetic Resonance Imaging and Biomarkers for Muscular D
Magnetic Resonance Imaging and Biomarkers for Muscular D
|
|
07-2015
|
A Multidisciplinary and Translational Approach to Hepato
A Multidisciplinary and Translational Approach to Hepato
|
|
07-2015
|
BI 201335 and BI 207127
BI 201335 and BI 207127
|
|
06-2015
|
TVR + SOF-CCC
TVR + SOF-CCC
|
|
06-2015
|
UF Clinical and Translational Science Award (KL2)
UF Clinical and Translational Science Award (KL2)
|
|
05-2015
|
UF Clinical Translational Science Award (TL1)
UF Clinical Translational Science Award (TL1)
|
|
05-2015
|
Bayer ONC-2010-19 IST
Bayer ONC-2010-19 IST
|
|
03-2015
|
HCV-TARGET FUNDING SOURCE: Genentech
HCV-TARGET FUNDING SOURCE: Genentech
|
|
02-2015
|
HCV-TARGET FUNDING SOURCE: VERTEX
HCV-TARGET FUNDING SOURCE: VERTEX
|
|
10-2014
|
P2938-0721 QUANTUM
P2938-0721 QUANTUM
|
|
08-2014
|
VAMC-BRRC IPA for Phillip Chase
VAMC-BRRC IPA for Phillip Chase
|
|
08-2014
|
GS-US-256-0124
GS-US-256-0124
|
|
06-2014
|
GS-US-248-0120
GS-US-248-0120
|
|
04-2014
|
P7977-0724 ATOMIC
P7977-0724 ATOMIC
|
|
03-2014
|
An Open-Label Pilot Study to Evaluate the Antiviral Acti
An Open-Label Pilot Study to Evaluate the Antiviral Acti
|
|
06-2013
|
VX11-222-106
VX11-222-106
|
|
04-2013
|
Mapatumumab HGS1012-c1077
Mapatumumab HGS1012-c1077
|
|
02-2013
|
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
|
|
02-2013
|
Abbott M13-386
Abbott M13-386
|
|
12-2012
|
P7977-0221
P7977-0221
|
|
09-2012
|
Zymo 526H04
Zymo 526H04
|
|
06-2012
|
UF Clinical Translational Science Institute
UF Clinical Translational Science Institute
|
|
04-2012
|
FISSION: P7977-1231
FISSION: P7977-1231
|
|
01-2012
|
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
RNDMZ OPN-LBL COMPAR EVAL OF CONVERSION FROM CALCINEURIN
|
|
10-2011
|
National Trends in the Prevalence of Thrombocytopenia
National Trends in the Prevalence of Thrombocytopenia
|
|
07-2011
|
Basic and Clinical Research Training in Gastroenterology
Basic and Clinical Research Training in Gastroenterology
|
|
06-2011
|
Conatus CTS-1027-03
Conatus CTS-1027-03
|
|
03-2011
|
VX07-950-108
VX07-950-108
|
|
01-2011
|
Debio 025-HCV-207
Debio 025-HCV-207
|
|
01-2011
|
VX-950-107 A Rollover Protocol of Telaprevir (VX-950) in
VX-950-107 A Rollover Protocol of Telaprevir (VX-950) in
|
|
12-2010
|
MV21542-Prophesys 3
MV21542-Prophesys 3
|
|
12-2010
|
MECHANISMS OF INNATE AND ADAPTIVE IMMUNITY IN HCV
MECHANISMS OF INNATE AND ADAPTIVE IMMUNITY IN HCV
|
|
10-2010
|
NV17590B
NV17590B
|
|
10-2010
|
VX950-TiDP24-C216
VX950-TiDP24-C216
|
|
09-2010
|
VX08-950-111
VX08-950-111
|
|
09-2010
|
NV19865/B
NV19865/B
|
|
07-2010
|
PV18369
PV18369
|
|
06-2010
|
AASLD NP/PA Clinical Hepatology Fellowship Program
AASLD NP/PA Clinical Hepatology Fellowship Program
|
|
06-2010
|
Banyan Liver Serodiagnostic Panel Results with Histologi
Banyan Liver Serodiagnostic Panel Results with Histologi
|
|
04-2010
|
Phase 2 Study of VX-950, Pegasys, and Copegus in HCV
Phase 2 Study of VX-950, Pegasys, and Copegus in HCV
|
|
03-2010
|
P7081-5103
P7081-5103
|
|
12-2009
|
Intercept PBC 747-202 INT-747
Intercept PBC 747-202 INT-747
|
|
12-2009
|
Pharmasset P7081-5101 Part 3
Pharmasset P7081-5101 Part 3
|
|
12-2009
|
RM012025-Alinia
RM012025-Alinia
|
|
12-2009
|
ACHIEVE 1 HGS1008-C1060
ACHIEVE 1 HGS1008-C1060
|
|
11-2009
|
VX06-950-106 Prove 3
VX06-950-106 Prove 3
|
|
10-2009
|
Wyeth 3173A1-200-US --HCV 796
Wyeth 3173A1-200-US --HCV 796
|
|
09-2009
|
NV17590
NV17590
|
|
09-2009
|
ALFR-HC-05
ALFR-HC-05
|
|
08-2009
|
FibroScan
FibroScan
|
|
06-2009
|
AASLD 2008 Advanced Hepatology Fellowship
AASLD 2008 Advanced Hepatology Fellowship
|
|
06-2009
|
AASLD 2008 NP/PA Fellowship for Rennie Mills
AASLD 2008 NP/PA Fellowship for Rennie Mills
|
|
01-2009
|
ML18124
ML18124
|
|
10-2008
|
NV-08A-006
NV-08A-006
|
|
06-2008
|
AASLD 2007 Advanced Hepatology Fellowship-Virginia Clark
AASLD 2007 Advanced Hepatology Fellowship-Virginia Clark
|
|
04-2008
|
Efficacy of JVRS-100 on HCV replication and Immune Funct
Efficacy of JVRS-100 on HCV replication and Immune Funct
|
|
09-2007
|
BASIC RESEARCH TRAINING IN GASTROENTEROLOGY AND
BASIC RESEARCH TRAINING IN GASTROENTEROLOGY AND
|
|
07-2007
|
A TRIAL OF ZADAXIN WITH TRANS ARTERIAL CHEMOEMBOLIZATION
A TRIAL OF ZADAXIN WITH TRANS ARTERIAL CHEMOEMBOLIZATION
|
|
04-2007
|
A MULTICENTERED DOUBLEBLINDED STUDY IN NONCIRRHOTIC PATI
A MULTICENTERED DOUBLEBLINDED STUDY IN NONCIRRHOTIC PATI
|
|
12-2006
|
A MULTICENTERED DOUBLE-BLINDED STUDY IN NONCIRRHOTIC PAT
A MULTICENTERED DOUBLE-BLINDED STUDY IN NONCIRRHOTIC PAT
|
|
11-2006
|
RNDMZD PLCB-CNTRL TRIAL OF BETAINE IN PATNTS W/ NONALCOH
RNDMZD PLCB-CNTRL TRIAL OF BETAINE IN PATNTS W/ NONALCOH
|
|
11-2006
|
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY COMPARING TH
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY COMPARING TH
|
|
08-2006
|
PHASE IV PILOT STUDY EVALUATING PEGASYS 180 UG OR 270 UG
PHASE IV PILOT STUDY EVALUATING PEGASYS 180 UG OR 270 UG
|
|
06-2006
|
AASLD-2005 NP/PA-Doug Senecal
AASLD-2005 NP/PA-Doug Senecal
|
|
06-2006
|
BASIC RESEARCH TRAINING IN GASTROENTEROLOGY AND
BASIC RESEARCH TRAINING IN GASTROENTEROLOGY AND
|
|
03-2006
|
NV17317: RANDMZD, MLTCTR, OPEN LABEL, PHASE IV STUDY EVA
NV17317: RANDMZD, MLTCTR, OPEN LABEL, PHASE IV STUDY EVA
|
|
02-2006
|
PHASE 1 STDY TO EVAL THE SAF, TOLERABILITY, AND PHARMACO
PHASE 1 STDY TO EVAL THE SAF, TOLERABILITY, AND PHARMACO
|
|
01-2006
|
ANTIVIRAL EFFICACY OF ALBUFERON IN THE HCV REPLICON MODE
ANTIVIRAL EFFICACY OF ALBUFERON IN THE HCV REPLICON MODE
|
|
01-2006
|
A 12 WEEK MULTI-CTR DBL-BLD RNDMZD PLCB-CNTRL DOSE RESPO
A 12 WEEK MULTI-CTR DBL-BLD RNDMZD PLCB-CNTRL DOSE RESPO
|
|
11-2005
|
...SAFETY AND ANTI-FIBROTIC EFFICACY OF INTERFERON-GAMMA
...SAFETY AND ANTI-FIBROTIC EFFICACY OF INTERFERON-GAMMA
|
|
08-2005
|
HEPATITIS C IN CLINICALLY DISCORDANT HEMOPHILIC SIBLINGS
HEPATITIS C IN CLINICALLY DISCORDANT HEMOPHILIC SIBLINGS
|
|
07-2005
|
2004 AASLD NP/PA CLINICAL HEPATOLOGY FELLOWSHIP PROGRAM
2004 AASLD NP/PA CLINICAL HEPATOLOGY FELLOWSHIP PROGRAM
|
|
06-2005
|
AASLD/SCHERING ADVANCED HEPATOLOGY FELLOWSHIP PROGRAM
AASLD/SCHERING ADVANCED HEPATOLOGY FELLOWSHIP PROGRAM
|
|
05-2005
|
DOSE-RANGING STUDY OF VIRAMIDINE IN COMBINATION WITH PEG
DOSE-RANGING STUDY OF VIRAMIDINE IN COMBINATION WITH PEG
|
|
12-2004
|
PROTL #02-LF-03: COMPARISON OF LIVER FIBROSIS SERODIAGNO
PROTL #02-LF-03: COMPARISON OF LIVER FIBROSIS SERODIAGNO
|
|
10-2004
|
A MULTIPLE RISING-DOSE STUDY OF FK788 IN SUBJECTS WITH
A MULTIPLE RISING-DOSE STUDY OF FK788 IN SUBJECTS WITH
|
|
06-2004
|
CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
|
|
12-2003
|
OBSRVTIONL STDY TO EVL 2 5 OLIGOANDEYLATE SYNTHETASE(OA
OBSRVTIONL STDY TO EVL 2 5 OLIGOANDEYLATE SYNTHETASE(OA
|
|
10-2003
|
A RDMIZED...SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIV
A RDMIZED...SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIV
|
|
06-2003
|
A RNDMZD OPN LBL PHS I/II STDY TO EVALUATE THE SFTY and PH
A RNDMZD OPN LBL PHS I/II STDY TO EVALUATE THE SFTY and PH
|
|
02-2003
|
IN VITRO STUDIES TO IDENTIFY HOST GENES OR PATHWAYS IN
IN VITRO STUDIES TO IDENTIFY HOST GENES OR PATHWAYS IN
|
|
07-2001
|
INTERLEUKIN 10 DAILY OR 3 TIMES PER WK FOR TREATMENT OF
INTERLEUKIN 10 DAILY OR 3 TIMES PER WK FOR TREATMENT OF
|
|
06-2001
|
CHARACTERIZATION OF HCV-SPECIFIC CYTOTOXIC T AYMPHOCYTES
CHARACTERIZATION OF HCV-SPECIFIC CYTOTOXIC T AYMPHOCYTES
|
|
03-2001
|
A DOUBLE-BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGIN
A DOUBLE-BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGIN
|
|
01-2001
|
3ILOT DOSE-FINDING STUDY OF MYCOPHENOLATE MOFETIL IN CHR
3ILOT DOSE-FINDING STUDY OF MYCOPHENOLATE MOFETIL IN CHR
|
|
05-2000
|
GENERATION AND CHARACTERIZATION OF HEPATITIS C VIRUS-SPE
GENERATION AND CHARACTERIZATION OF HEPATITIS C VIRUS-SPE
|
|
08-1999
|
EFFECT OF INTERLEUKIN 10 (IL-10) IN SUBJECTS WITH CHRONI
EFFECT OF INTERLEUKIN 10 (IL-10) IN SUBJECTS WITH CHRONI
|
|
01-1999
|
GENERATION AND CHARACTERIZATION OF HEPATITIS C VIRUS-
GENERATION AND CHARACTERIZATION OF HEPATITIS C VIRUS-
|
